Siegel RL, Giaquinto AN, Jemal A. Most cancers statistics, 2024. CA Most cancers J Clin. 2024;74:12–49.
Dai C, Dehm SM, Sharifi N. Concentrating on the androgen signaling axis in prostate most cancers. J Clin Oncol. 2023;41:4267–78.
Bishop JL, Thaper D, Vahid S, Davies A, Ketola Okay, Kuruma H, et al. The grasp neural transcription issue BRN2 Is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate most cancers. Most cancers Discov. 2017;7:54–71.
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate most cancers. Nat Med. 2016;22:298–305.
Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, et al. Mixed TP53 and RB1 loss promotes prostate most cancers resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 2020;31:107669.
Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran LL, Agrawal P, et al. Aberrant activation of a gastrointestinal transcriptional circuit in prostate most cancers mediates castration resistance. Most cancers Cell. 2017;32:792–806.
Tang FY, Xu D, Wang SQ, Wong CK, Martinez-Fundichely A, Lee CJ, et al. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science. 2022;376:eabe1505.
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and development of human prostate most cancers. Nat Genet. 1995;9:401–6.
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational panorama of deadly castration-resistant prostate most cancers. Nature. 2012;487:239–43.
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative scientific genomics of superior prostate most cancers. Cell. 2015;162:454.
Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Upkeep of intratumoral androgens in metastatic prostate most cancers: a mechanism for castration-resistant tumor development. Most cancers Res. 2008;68:4447–54.
Stanbrough M, Bubley GJ, Ross Okay, Golub TR, Rubin MA, Penning TM, et al. Elevated expression of genes changing adrenal androgens to testosterone in androgen-independent prostate most cancers. Most cancers Res. 2006;66:2815–25.
Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, et al. Proof of restricted contributions for intratumoral steroidogenesis in prostate most cancers. Most cancers Res. 2010;70:1256–64.
Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal suggestions regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate most cancers. Most cancers Cell. 2011;19:575–86.
Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen Okay, et al. Reprogramming regular human epithelial tissues to a typical, deadly neuroendocrine most cancers lineage. Science. 2018;362:91–5.
Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Medical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate most cancers: a multi-institutional potential examine. J Clin Oncol. 2018;36:2492–503.
Li HY, Wang LL, Li Z, Geng X, Li M, Tang Q, et al. SOX2 has twin capabilities as a regulator within the development of neuroendocrine prostate most cancers. Lab Make investments. 2020;100:570–82.
Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang Y, et al. Polycomb-mediated silencing in neuroendocrine prostate most cancers. Clin Epigenetics. 2015;7:40.
Zhang DX, Hu Q, Liu XZ, Ji YB, Chao HP, Liu Y, et al. Intron retention is a trademark and spliceosome represents a therapeutic vulnerability in aggressive prostate most cancers. Nat Commun. 2020;11:2089.
Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional applications mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate most cancers. Most cancers Res. 2012;72:3457–62.
Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, et al. Fast induction of androgen receptor splice variants by androgen deprivation in prostate most cancers. Clin Most cancers Res. 2014;20:1590–600.
Li YA, Donmez N, Sahinalp C, Xie N, Wang YW, Xue H, et al. SRRM4 drives neuroendocrine transdifferentiation of prostate adenocarcinoma underneath androgen receptor pathway inhibition. Eur Urol. 2017;71:68–78.
Zhang XT, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, et al. SRRM4 expression and the lack of REST exercise might promote the emergence of the neuroendocrine phenotype in castration-resistant prostate most cancers. Clin Most cancers Res. 2015;21:4698–708.
Lee AR, Gan Y, Tang YX, Dong XS. A novel mechanism of SRRM4 in selling neuroendocrine prostate most cancers improvement by way of a pluripotency gene community. EBioMedicine. 2018;35:167–77.
Jimenez-Vacas JM, Herrero-Aguayo V, Montero-Hidalgo AJ, Gomez-Gomez E, Fuentes-Fayos AC, Leon-Gonzalez AJ, et al. Dysregulation of the splicing equipment is instantly related to aggressiveness of prostate most cancers. EBioMedicine. 2020;51:102547.
Wang BD, Ceniccola Okay, Hwang S, Andrawis R, Horvath A, Freedman JA, et al. Various splicing promotes tumour aggressiveness and drug resistance in African American prostate most cancers. Nat Commun. 2017;8:15921.
Han JH, Xiong J, Wang D, Fu XD. Pre-mRNA splicing: the place and when within the nucleus. Traits Cell Biol. 2011;21:336–43.
Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of other splicing complexity within the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40:1413–5.
Jiang W, Chen L. Various splicing: human illness and quantitative evaluation from high-throughput sequencing. Comput Struct Biotechnol J. 2021;19:183–95.
Marasco LE, Kornblihtt AR. The physiology of other splicing. Nat Rev Mol Cell Biol. 2023;24:242–54.
Black DL. Mechanisms of other pre-messenger RNA splicing. Annu Rev Biochem. 2003;72:291–336.
Kahles A, Lehmann KV, Toussaint NC, Huser M, Stark SG, Sachsenberg T, et al. Complete evaluation of other splicing throughout tumors from 8,705 sufferers. Most cancers Cell. 2018;34:211–24.e6.
Rappsilber J, Ryder U, Lamond AI, Mann M. Giant-scale proteomic evaluation of the human spliceosome. Genome Res. 2002;12:1231–45.
Barbosa-Morais NL, Carmo-Fonseca M, Aparicio S. Systematic genome-wide annotation of spliceosomal proteins reveals differential gene household enlargement. Genome Res. 2006;16:66–77.
Cvitkovic I, Jurica MS. Spliceosome database: a device for monitoring elements of the spliceosome. Nucleic Acids Res. 2013;41:D132–D41.
Patel AA, Steitz JA. Splicing double: insights from the second spliceosome. Nat Rev Mol Cell Biol. 2003;4:960–70.
Fica SM, Tuttle N, Novak T, Li NS, Lu J, Koodathingal P, et al. RNA catalyses nuclear pre-mRNA splicing. Nature. 2013;503:229–34.
Corridor SL, Padgett RA. Requirement of U12 snRNA for in vivo splicing of a minor class of eukaryotic nuclear pre-mRNA introns. Science. 1996;271:1716–8.
Corridor SL, Padgett RA. Conserved sequences in a category of uncommon eukaryotic nuclear introns with nonconsensus splice websites. J Mol Biol. 1994;239:357–65.
Akinyi MV, Frilander MJ. On the intersection of main and minor spliceosomes: crosstalk mechanisms and their influence on gene expression. Entrance Genet. 2021;12:700744.
Pessa HKJ, Will CL, Meng XJ, Schneider C, Watkins NJ, Perälä N, et al. Minor spliceosome elements are predominantly localized within the nucleus. Proc Natl Acad Sci USA. 2008;105:8655–60.
König H, Matter N, Bader R, Thiele W, Müller F. Splicing segregation: the minor spliceosome acts outdoors the nucleus and controls cell proliferation. Cell. 2007;131:718–29.
Pal Okay, Kolev NG, Shu MD, Steitz JA. Minor-class splicing happens within the nucleus of the oocyte. RNA. 2008;14:1459–62.
Olthof AM, Hyatt KC, Kanadia RN. Minor intron splicing revisited: identification of recent minor intron-containing genes and tissue-dependent retention and various splicing of minor introns. BMC Genom. 2019;20:686.
Sheth N, Roca X, Hastings ML, Roeder T, Krainer AR, Sachidanandam R. Complete splice-site evaluation utilizing comparative genomics. Nucleic Acids Res. 2006;34:3955–67.
Matlin AJ, Clark F, Smith CWJ. Understanding various splicing: in the direction of a mobile code. Nat Rev Mol Cell Biol. 2005;6:386–98.
Caputi M, Zahler AM. Dedication of the RNA binding specificity of the heterogeneous nuclear ribonucleoprotein (hnRNP) H/H′/F/2H9 household. J Biol Chem. 2001;276:43850–9.
Xiao X, Wang Z, Jang M, Burge CB. Coevolutionary networks of splicing cis-regulatory parts. Proc Natl Acad Sci USA. 2007;104:18583–8.
Pandit S, Zhou Y, Shiue L, Coutinho-Mansfield G, Li H, Qiu J, et al. Genome-wide evaluation reveals SR protein cooperation and competitors in regulated splicing. Mol Cell. 2013;50:223–35.
Zarnack Okay, König J, Tajnik M, Martincorena I, Eustermann S, Stévant I, et al. Direct competitors between hnRNP C and U2AF65 protects the transcriptome from the exonization of parts. Cell. 2013;152:453–66.
Goren A, Ram O, Amit M, Keren H, Lev-Maor G, Vig I, et al. Comparative evaluation identifies exonic splicing regulatory sequences – the complicated definition of enhancers and silencers. Mol Cell. 2006;22:769–81.
Eperon LP, Graham IR, Griffiths AD, Eperon IC. Results of RNA secondary construction on various splicing of pre-messenger RNA – is folding restricted to a area behind the transcribing RNA-polymerase. Cell. 1988;54:393–401.
de la Mata M, Alonso CR, Kadener S, Fededa JP, Blaustein M, Pelisch F, et al. A sluggish RNA polymerase II impacts various splicing in vivo. Mol Cell. 2003;12:525–32.
Yoshida Okay, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing equipment in myelodysplasia. Nature. 2011;478:64–9.
Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384–95.
Wang LL, Lawrence MS, Wan YZ, Stojanov P, Sougnez C, Stevenson Okay, et al. SF3B1 and different novel most cancers genes in power lymphocytic leukemia. N Engl J Med. 2011;365:2497–506.
Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is outlined by distinct somatic mutations. Blood. 2015;125:1367–76.
Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in development and relapse. Nature. 2015;526:525–30.
Bigot J, Lalanne AI, Lucibello F, Gueguen P, Houy A, Dayot S, et al. Splicing patterns in SF3B1-mutated uveal melanoma generate shared immunogenic tumor-specific neoepitopes. Most cancers Discov. 2021;11:1938–51.
Harbour JW, Roberson EDO, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing issue SF3B1 in uveal melanoma. Nat Genet. 2013;45:133–5.
Martin M, Masshofer L, Temming P, Rahmann S, Metz C, Bornfeld N, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013;45:933–6.
Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150:1107–20.
Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou XQ, et al. Panorama of somatic mutations in 560 breast most cancers whole-genome sequences. Nature. 2016;534:47–54.
Bailey P, Chang DK, Nones Okay, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses determine molecular subtypes of pancreatic most cancers. Nature. 2016;531:47–52.
Czubaty A, Piekielko-Witkowska A. Protein kinases that phosphorylate splicing components: roles in most cancers improvement, development and attainable therapeutic choices. Int J Biochem Cell B. 2017;91:102–15.
Chang Y, Wu Q, Tian T, Li L, Guo X, Feng Z, et al. The affect of SRPK1 on glioma apoptosis, metastasis, and angiogenesis via the PI3K/Akt signaling pathway underneath normoxia. Tumour Biol. 2015;36:6083–93.
Zhou B, Li Y, Deng Q, Wang H, Wang Y, Cai B, et al. SRPK1 contributes to malignancy of hepatocellular carcinoma via a attainable mechanism involving PI3K/Akt. Mol Cell Biochem. 2013;379:191–9.
Mavrou A, Brakspear Okay, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, et al. Serine-arginine protein kinase 1 (SRPK1) inhibition as a possible novel focused therapeutic technique in prostate most cancers. Oncogene. 2015;34:4311–9.
Amin EM, Oltean S, Hua J, Gammons MVR, Hamdollah-Zadeh M, Welsh GI, et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis goal by altering VEGF splicing. Most cancers Cell. 2011;20:768–80.
Liu YY, Conaway L, Bethard JR, Al-Ayoubi AM, Bradley AT, Zheng H, et al. Phosphorylation of the choice mRNA splicing issue 45 (SPF45) by Clk1 regulates its splice website utilization, cell migration and invasion. Nucleic Acids Res. 2013;41:4949–62.
Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Various isoform regulation in human tissue transcriptomes. Nature. 2008;456:470–6.
Olivieri JE, Dehghannasiri R, Wang PL, Jang S, de Morree A, Tan SY, et al. RNA splicing applications outline tissue compartments and cell sorts at single-cell decision. eLife. 2021;10:e70692.
Xu CA, Zhang JZ. Mammalian round RNAs end result largely from splicing errors. Cell Rep. 2021;36:109439.
Lewis BP, Inexperienced RE, Brenner SE. Proof for the widespread coupling of other splicing and nonsense-mediated mRNA decay in people. Proc Natl Acad Sci USA. 2003;100:189–92.
Buljan M, Chalancon G, Eustermann S, Wagner GP, Fuxreiter M, Bateman A, et al. Tissue-specific splicing of disordered segments that embed binding motifs rewires protein interplay networks. Mol Cell. 2012;46:871–83.
Ellis JD, Barrios-Rodiles M, Çolak R, Irimia M, Kim T, Calarco JA, et al. Tissue-specific various splicing remodels protein-protein interplay networks. Mol Cell. 2012;46:884–92.
Sulakhe D, D’Souza M, Wang S, Balasubramanian S, Athri P, Xie BQ, et al. Exploring the purposeful influence of other splicing on human protein isoforms utilizing accessible annotation sources. Temporary Bioinform. 2019;20:1754–68.
Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, et al. A section I examine of the warmth shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to sufferers with superior stable tumors. Clin Most cancers Res. 2011;17:1561–70.
Lin L, Park JW, Ramachandran S, Zhang Y, Tseng YT, Shen SH, et al. Transcriptome sequencing reveals aberrant various splicing in Huntington’s illness. Hum Mol Genet. 2016;25:3454–66.
Raj T, Li YI, Wong G, Humphrey J, Wang MH, Ramdhani S, et al. Integrative transcriptome analyses of the growing old mind implicate altered splicing in Alzheimer’s illness susceptibility. Nat Genet. 2018;50:1584–92.
Bhattacharya A, Vo DD, Jops C, Kim M, Wen CY, Hervoso JL, et al. Isoform-level transcriptome-wide affiliation uncovers genetic threat mechanisms for neuropsychiatric issues within the human mind. Nat Genet. 2023;55:2117–28.
Zhang Y, Yan L, Zeng J, Zhou H, Liu H, Yu G, et al. Pan-cancer evaluation of scientific relevance of other splicing occasions in 31 human cancers. Oncogene. 2019;38:6678–95.
Al Abo M, Hyslop T, Qin XD, Owzar Okay, George DJ, Patierno SR, et al. Differential various RNA splicing and transcription occasions between tumors from African American and White sufferers in The Most cancers Genome Atlas. Genomics. 2021;113:1234–46.
Lu ZX, Huang Q, Park JW, Shen SH, Lin L, Tokheim CJ, et al. Transcriptome-wide panorama of pre-mRNA various splicing related to metastatic colonization. Mol Most cancers Res. 2015;13:305–18.
Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, et al. H3B-8800, an orally accessible small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018;24:497–504.
Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, et al. Outcomes of a scientific trial of H3B-8800, a splicing modulator, in sufferers with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or power myelomonocytic leukemia (CMML). Blood. 2019;134:673.
Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, et al. Closing outcomes of a section 2, open-label examine of indisulam, idarubicin, and cytarabine in sufferers with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Most cancers. 2018;124:2758–65.
Latonen L, Afyounian E, Jylhä A, Nättinen J, Aapola U, Annala M, et al. Integrative proteomics in prostate most cancers uncovers robustness in opposition to genomic and transcriptomic aberrations throughout illness development. Nat Commun. 2018;9:1176.
Nagaraj N, Wisniewski JR, Geiger T, Cox J, Kircher M, Kelso J, et al. Deep proteome and transcriptome mapping of a human most cancers cell line. Mol Syst Biol. 2011;7:548.
Sinha A, Huang V, Livingstone J, Wang J, Fox NS, Kurganovs N, et al. The proteogenomic panorama of curable prostate most cancers. Most cancers Cell. 2019;35:414–27.
Iglesias-Gato D, Thysell E, Tyanova S, Crnalic S, Santos A, Lima TS, et al. The proteome of prostate most cancers bone metastasis reveals heterogeneity with prognostic implications. Clin Most cancers Res. 2018;24:5433–44.
Varambally S, Yu JJ, Laxman B, Rhodes DR, Mehra R, Tomlins SA, et al. Integrative genomic and proteomic evaluation of prostate most cancers reveals signatures of metastatic development. Most cancers Cell. 2005;8:393–406.
Slawin KM, Shariat SF, Nguyen C, Leventis AK, Music WT, Kattan HW, et al. Detection of metastatic prostate most cancers utilizing a splice variant-specific reverse transcriptase-polymerase chain response assay for human glandular kallikrein. Most cancers Res. 2000;60:7142–8.
Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, et al. Cyclin D1 splice variants: polymorphism, threat, and isoform-specific regulation in prostate most cancers. Clin Most cancers Res. 2009;15:5338–49.
Tanaka T, Isono T, Yoshiki T, Yuasa T, Okada Y. A novel type of prostate-specific antigen transcript produced by various splicing. Most cancers Res. 2000;60:56–9.
Weissensteiner T. Prostate most cancers cells present a virtually 100-fold enhance within the expression of the longer of two alternatively spliced mRNAs of the prostate-specific membrane antigen (PSM). Nucleic Acids Res. 1998;26:687.
Su SL, Huang IP, Honest WR, Powell CT, Heston WDW. Alternatively spliced variants of prostate-specific membrane antigen RNA – ratio of expression as a possible measurement of development. Most cancers Res. 1995;55:1441–3.
Zhang CL, Li HR, Fan JB, Wang-Rodriguez J, Downs T, Fu XD, et al. Profiling alternatively spliced mRNA isoforms for prostate most cancers classification. BMC Bioinform. 2006;7:202.
Mou ZF, Spencer J, Mcgrath JS, Harries LW. Complete evaluation of other splicing throughout a number of transcriptomic cohorts reveals prognostic signatures in prostate most cancers. Hum Genom. 2023;17:97.
Zhu JW, Zhang JY, Hu P, Fan MX, Music DW, Yin HB, et al. Identification of bone metastatic and prognostic various splicing signatures in prostate adenocarcinoma. Biochem Genet. 2023;61:2242–59.
Zhang H, Tian JF, Ren SX, Han BA, Tian RA, Zuo XY, et al. Comprehensively evaluation of splicing components to assemble prognosis prediction classifier in prostate most cancers. J Cell Mol Med. 2023;27:2684–700.
Wu TQ, Wang WF, Wang YH, Yao MF, Du LL, Zhang XM, et al. Complete evaluation of other splicing profiling reveals novel occasions related to prognosis and the infiltration of immune cells in prostate most cancers. Transl Androl Urol. 2021;10:3056–68.
Zhao JY, Chang LC, Gu XE, Liu J, Solar B, Wei X. Systematic profiling of other splicing signature reveals prognostic predictor for prostate most cancers. Most cancers Sci. 2020;111:3020–31.
Cao ZX, Xiao GA, Zhang W, Ji J, Ye C, Liu D, et al. Complete investigation of other splicing and improvement of a prognostic threat rating for prostate most cancers based mostly on six-gene signatures. J Most cancers. 2019;10:5585–96.
Huang ZG, He RQ, Mo ZN. Prognostic worth and potential operate of splicing occasions in prostate adenocarcinoma. Int J Oncol. 2018;53:2473–87.
Ko HK, Berk M, Chung YM, Willard B, Bareja R, Rubin M, et al. Lack of an androgen-inactivating and isoform-specific HSD17B4 splice type allows emergence of castration-resistant prostate most cancers. Cell Rep. 2018;22:809–19.
Olender J, Wang BD, Ching T, Garmire LX, Garofano Okay, Ji YM, et al. A novel FGFR3 splice variant preferentially expressed in African American prostate most cancers drives aggressive phenotypes and docetaxel resistance. Mol Most cancers Res. 2019;17:2115–25.
Tan MHE, Li J, Xu HE, Melcher Okay, Yong EL. Androgen receptor: construction, position in prostate most cancers and drug discovery. Acta Pharm Sin. 2015;36:3–23.
Cao SB, Zhan Y, Dong Y. Rising information on androgen receptor splice variants in prostate most cancers. Endocr Relat Most cancers. 2016;23:T199–T210.
Antonarakis ES, Lu CX, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate most cancers. N Engl J Med. 2014;371:1028–38.
Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, et al. Expression of AR-V7 and ARv(567es) in circulating tumor cells correlates with outcomes to taxane remedy in males with metastatic prostate most cancers handled in TAXYNERGY. Clin Most cancers Res. 2019;25:1880–8.
Solar SH, Sprenger CCT, Vessella RL, Haugk Okay, Soriano Okay, Mostaghel EA, et al. Castration resistance in human prostate most cancers is conferred by a steadily occurring androgen receptor splice variant. J Clin Investig. 2010;120:2715–30.
Hu R, Dunn TA, Wei SZ, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate most cancers. Most cancers Res. 2009;69:16–22.
Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel exon generates a constitutively energetic androgen receptor that mediates prostate most cancers remedy resistance. Most cancers Res. 2008;68:5469–77.
Ohnishi T, Shirane M, Nakayama KI. SRRM4-dependent neuron-specific various splicing of protrudin transcripts regulates neurite outgrowth. Sci Rep. 2017;7:41130.
Augspach A, Drake KD, Roma L, Qian EL, Lee SR, Clarke D, et al. Minor intron splicing is vital for survival of deadly prostate most cancers. Mol Cell. 2023;83:1983–2002.
Takayama Okay, Suzuki T, Fujimura T, Yamada Y, Takahashi S, Homma Y, et al. Dysregulation of spliceosome gene expression in superior prostate most cancers by RNA-binding protein PSF. Proc Natl Acad Sci USA. 2017;114:10461–6.
Jonsson L, Gaber A, Ulmert D, Uhlén M, Bjartell A, Jirström Okay. Excessive RBM3 expression in prostate most cancers independently predicts a diminished threat of biochemical recurrence and illness development. Diagn Pathol. 2011;6:91.
Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, et al. Molecular evolution of early-onset prostate most cancers identifies molecular threat markers and scientific trajectories. Most cancers Cell. 2018;34:996–1011.
Armenia J, Wankowicz SAM, Liu D, Gao JJ, Kundra R, Reznik E, et al. The lengthy tail of oncogenic drivers in prostate most cancers. Nat Genet. 2018;50:645–51.
Munkley J, Li L, Krishnan SRG, Hysenaj G, Scott E, Dalgliesh C, et al. Androgen-regulated transcription of ESRP2 drives various splicing patterns in prostate most cancers. eLife. 2019;8:e47678.
Shah Okay, Gagliano T, Garland L, O’Hanlon T, Bortolotti D, Gentili V, et al. Androgen receptor signaling regulates the transcriptome of prostate most cancers cells by modulating world various splicing. Oncogene. 2020;39:6172–89.
Ushigome M, Ubagai T, Fukuda H, Tsuchiya N, Sugimura T, Takatsuka J, et al. Up-regulation of hnRNP A1 gene in sporadic human colorectal cancers. Int J Oncol. 2005;26:635–40.
David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins managed by c-Myc decontrol pyruvate kinase mRNA splicing in most cancers. Nature. 2010;463:364–U114.
Chena X, Yang HT, Zhang B, Phillips JW, Cheng DH, Rigo F, et al. The RNA- binding proteins hnRNP H and F regulate splicing of a MYC- dependent HRAS exon in prostate most cancers cells. Proc Natl Acad Sci USA. 2023;120:e2220190120.
Phillips JW, Pan Y, Tsai BL, Xie ZJ, Demirdjian L, Xiao W, et al. Pathway-guided evaluation identifies Myc-dependent various pre-mRNA splicing in aggressive prostate cancers. Proc Natl Acad Sci USA. 2020;117:5269–79.
Del Giudice M, Foster JG, Peirone S, Rissone A, Caizzi L, Gaudino F, et al. FOXA1 regulates various splicing in prostate most cancers. Cell Rep. 2022;40:111404.
Fei T, Chen YW, Xiao TF, Li W, Cato L, Zhang P, et al. Genome-wide CRISPR display identifies HNRNPL as a prostate most cancers dependency regulating RNA splicing. Proc Natl Acad Sci USA. 2017;114:E5207–E5215.
Ding FY, Su CJ, Edmonds KK, Liang GH, Elowitz MB. Dynamics and purposeful roles of splicing issue autoregulation. Cell Rep. 2022;39:110985.
Fu XD, Ares M. Context-dependent management of other splicing by RNA-binding proteins. Nat Rev Genet. 2014;15:689–701.
Rawat C, Ben-Salem S, Singh N, Chauhan G, Rabljenovic A, Vaghela V, et al. Prostate most cancers development depends on the mitotic kinase citron kinase. Most cancers Res. 2023;83:4142–60.
Belali T, Wodi C, Clark B, Cheung MK, Craig TJ, Wheway G, et al. WT1 prompts transcription of the splice issue kinase SRPK1 gene in PC3 and K562 most cancers cells within the absence of corepressor BASP1. BBA Gene Regul Mech. 2020;1863:194642.
Alanazi IO, Alamery SF, Ebrahimie E, Mohammadi-Dehcheshmeh M. Splice-disrupt genomic variants in prostate most cancers. Mol Biol Rep. 2022;49:4237–46.
Wang YR, Freedman JA, Liu HL, Moorman PG, Hyslop T, George DJ, et al. Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate most cancers. Int J Most cancers. 2017;141:731–43.
Xiao FK, Zhang P, Wang Y, Tian YJ, James M, Huang CC, et al. Single-nucleotide polymorphism rs13426236 contributes to an elevated prostate most cancers threat by way of regulating splicing variant 4. Mol Carcinog. 2020;59:45–55.
Takeshima Y, Nishio H, Sakamoto H, Nakamura H, Matsuo M. Modulation of in-vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J Clin Investig. 1995;95:515–20.
Alter J, Lou F, Rabinowitz A, Yin HF, Rosenfeld J, Wilton SD, et al. Systemic supply of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med. 2006;12:175–7.
Jiménez-Vacas JM, Herrero-Aguayo V, Gómez-Gómez E, León-González AJ, Sáez-Martínez P, Alors-Pérez E, et al. Spliceosome part SF3B1 as novel prognostic biomarker and therapeutic goal for prostate most cancers. Transl Res. 2019;212:89–103.
Alors-Perez E, Blázquez-Encinas R, Alcalá S, Viyuela-García C, Pedraza-Arevalo S, Herrero-Aguayo V, et al. Dysregulated splicing issue SF3B1 unveils a twin therapeutic vulnerability to focus on pancreatic most cancers cells and most cancers stem cells with an anti-splicing drug. J Exp Clin Most cancers Res. 2021;40:382.
Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami Okay, et al. Spliceostatin A targets SF3b and inhibits each splicing and nuclear retention of pre-mRNA. Nat Chem Biol. 2007;3:576–83.
Kotake Y, Sagane Okay, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, et al. Splicing issue SF3b as a goal of the antitumor pure product pladienolide. Nat Chem Biol. 2007;3:570–5.
Ghosh AK, Lv Okay, Ma NC, Cárdenas EL, Effenberger KA, Jurica MS. Design, synthesis and in vitro splicing inhibition of desmethyl and carba-derivatives of herboxidiene. Org Biomol Chem. 2016;14:5263–71.
Kawamura N, Nimura Okay, Saga Okay, Ishibashi A, Kitamura Okay, Nagano H, et al. SF3B2-mediated RNA splicing drives human prostate most cancers development. Most cancers Res. 2019;79:5204–17.
Yoshikawa Y, Ishibashi A, Takehara T, Suzuki T, Murai Okay, Kaneda Y, et al. Design and synthesis of 1,2-deoxy-pyranose derivatives of spliceostatin A towards prostate most cancers therapy. ACS Med Chem Lett. 2020;11:1310–5.
Hirabayashi S, Tsuyuguchi Y, Li Y, Ohta N, Yoshikawa Y, Lin BZ, et al. Design and synthesis of 4-acetoxypentanamide derivatives of spliceostatin A and their organic analysis in the direction of prostate most cancers therapy. Bioorg Med Chem Lett. 2023;91:129333.
Carabet LA, Leblanc E, Lallous N, Morin H, Ghaidi F, Lee J, et al. Pc-aided discovery of small molecules concentrating on the RNA splicing exercise of hnRNP A1 in castration-resistant prostate most cancers. Molecules. 2019;24:763.
Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Biologic and scientific significance of androgen receptor variants in castration resistant prostate most cancers. Endocr Relat Most cancers. 2014;21:T87–T103.
Melnyk JE, Steri V, Nguyen HG, Hann B, Feng FY, Shokat KM. The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate most cancers cells. Bioorgan Med Chem. 2020;28:115712.
Ferraldeschi R, Welti J, Powers MV, Yuan W, Smyth T, Seed G, et al. Second-generation HSP90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate most cancers cells. Most cancers Res. 2016;76:2731–42.
Gillis JL, Selth LA, Centenera MM, Townley SL, Solar S, Plymate SR, et al. Constitutively-active androgen receptor variants operate independently of the HSP90 chaperone however don’t confer resistance to HSP90 inhibitors. Oncotarget. 2013;4:691–704.
Shafi AA, Cox MB, Weigel NL. Androgen receptor splice variants are proof against inhibitors of Hsp90 and FKBP52, which alter androgen receptor exercise and expression. Steroids. 2013;78:548–54.
Li L, Zheng JX, Stevens M, Oltean S. A repositioning display utilizing an FGFR2 splicing reporter reveals compounds that regulate epithelial-mesenchymal transitions and inhibit development of prostate most cancers xenografts. Mol Ther Strategies Clin Dev. 2022;25:147–57.
Wang L, Gong SS, Zhang X, Azhar Z, Chen JL. Investigation of the regulatory results of synthesized antisense oligonucleotides on androgen receptor (AR) exon 3 splicing in prostate most cancers cells. Gene. 2023;866:147330.
Bauman JA, Li SD, Yang A, Huang L, Kole R. Anti-tumor exercise of splice-switching oligonucleotides. Nucleic Acids Res. 2010;38:8348–56.
Mercatante DR, Mohler JL, Kole R. Mobile response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic brokers. J Biol Chem. 2002;277:49374–82.
Brambilla C, Folini M, Gandellini P, Daprai L, Daidone MG, Zaffaroni N. Oligomer-mediated modulation of hTERT various splicing induces telomerase inhibition and cell development decline in human prostate most cancers cells. Cell Mol Life Sci. 2004;61:1764–74.
Hu Y, Dobi A, Sreenath T, Prepare dinner C, Tadase AY, Ravindranath L, et al. Delineation of TMPRSS2-ERG splice variants in prostate most cancers. Clin Most cancers Res. 2008;14:4719–25.
Li L, Hobson L, Perry L, Clark B, Heavey S, Haider A, et al. Concentrating on the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic technique in prostate most cancers. Br J Most cancers. 2020;123:1024–32.
Yoshida M, Oda C, Mishima Okay, Tsuji I, Obika S, Shimojo M. An antisense amido-bridged nucleic acid gapmer oligonucleotide concentrating on SRRM4 alters REST splicing and reveals anti-tumor results in small cell lung most cancers and prostate most cancers cells. Most cancers Cell Int. 2023;23:8.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for superior prostate most cancers. N Engl J Med. 2004;351:1502–12.
Ciccarese C, Santoni M, Massari F. Chemohormonal remedy in hormone-sensitive prostate most cancers. N Engl J Med. 2016;374:286.
Zhou YH, Li F, Zou BY, Zhou XF, Luo LM, Dong SC, et al. β-Arrestin2 promotes docetaxel resistance of castration-resistant prostate most cancers by way of selling hnRNP A1-mediated PKM2 various splicing. Discov Oncol. 2023;14:215.
Nakamura KDM, Tilli TM, Wanderley JL, Palumbo A, Mattos RM, Ferreira AC, et al. Osteopontin splice variants expression is concerned on docetaxel resistance in PC3 prostate most cancers cells. Tumor Biol. 2016;37:2655–63.
Shim M, Kim Y, Park Y, Ahn H. Taxane-based chemotherapy induced androgen receptor splice variant 7 in sufferers with castration-resistant prostate most cancers: a tissue-based evaluation. Sci Rep. 2019;9:16794.
Antonarakis ES, Lu CX, Luber B, Wang H, Chen Y, Nakazawa M. et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in sufferers with metastatic castration-resistant prostate most cancers. JAMA Oncol. 2015;1:582–91.
Hu Y, Dobi A, Sreenath T, Prepare dinner C, Tadase AY, Ravindranath L, et al. Delineation of splice variants in prostate most cancers. Clin Most cancers Res. 2008;14:4719–25.
Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, et al. Frequency of the TMPRSS2:ERG gene fusion is elevated in average to poorly differentiated prostate cancers. J Clin Pathol. 2007;60:1238–43.
Music HB, Weinstein HNW, Allegakoen P, Wadsworth MH, Xie J, Yang HK, et al. Single-cell evaluation of human main prostate most cancers reveals the heterogeneity of tumor-associated epithelial cell states. Nat Commun. 2022;13:141.
Araki S, Ohori M, Yugami M. Concentrating on pre-mRNA splicing in cancers: roles, inhibitors, and therapeutic alternatives. Entrance Oncol. 2023;13:1152087.
Vigevani L, Gohr A, Webb T, Irimia M, Valcárcel J. Molecular foundation of differential 3′ splice website sensitivity to anti-tumor medication concentrating on U2 snRNP. Nat Commun. 2017;8:2100.
Hasegawa M, Miura T, Kuzuya Okay, Inoue A, Ki SW, Horinouchi S, et al. Identification of SAP155 because the goal of GEX1A (herboxidiene), an antitumor pure product. ACS Chem Biol. 2011;6:229–33.
Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, Veitch J. et al. Various splicing and differential gene expression in colon most cancers detected by a complete genome exon array. BMC Genom. 2006;7:325
Frey Okay, Fiechter M, Schwager Okay, Belloni B, Barysch MJ, Neri D, et al. Totally different patterns of fibronectin and tenascin-C splice variants expression in main and metastatic melanoma lesions. Exp Dermatol. 2011;20:685–8.
Kelly WK, Danila DC, Edenfield WJ, Aggarwal RR, Petrylak DP, Sartor AO, et al. Section I examine of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune remedy, in sufferers with metastatic castration-resistant prostate most cancers (mCRPC). J Clin Oncol. 2020;38:TPS5589.
